Abstract
Question Is ultra-short-wave diathermy (USWD) safe and effective in coronavirus disease 2019 (COVID-19) ?
Design Single-centre, evaluator-blinded, two-arm, parallel design, randomized controlled clinical trial.
Participants Moderate and severe COVID-19 patients with acute respiratory syndrome.
Intervention USWD for 10 minutes twice daily for 12 consecutive days along with standard medical treatment (USWD group, n = 25), versus standard medical treatment alone (control group, n = 25).
Outcome measures The primary outcomes were the duration of recovery and negative conversion rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on days 7, 14, 21, and 28. Secondary outcomes included clinical status (seven-category ordinal and systemic inflammatory response syndrome (SIRS) scores), computed tomography (CT), routine blood tests, and adverse events.
Results Time to clinical recovery (USWD 36.84±9.93 vs. control 43.56±12.15, P = 0.037) was significantly shortened with a between-group difference of 6.72 days. Clinical status was improved with significant between-group differences on day 28 (SIRS, P = 0.011; seven-category scale, P = 0.003). The rate of RNA negative conversion at days 7 (P = 0.066), 14 (P = 0.239), 21 (P = 0.269), and 28 (P = 0.490) was statistically insignificant. Moreover, insignificant differences were observed in the artificial intelligence-assisted CT analysis. No treatment-associated adverse events or worsening of pulmonary fibrosis were observed.
Conclusion USWD, as adjunctive therapy, shortened the recovery course and improved clinical status of patients with COVID-19 without aggravating pulmonary fibrosis. the findings are limited due to the small sample size and early termination.
Registration ChiCTR2000029972
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2000029972
Funding Statement
The study was funded by the National Key Research and Development program(NO:2020YFC08845600).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
this randomized controlled trial was approved by the ethics committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (certificate of approval number TJ-C20200127)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This single-center, evaluator-blinded, two-arm, parallel design, randomized controlled clinical trial was aimed to evaluate the safety and efficacy of ultra-short-wave diathermy (USWD) in coronavirus disease 2019 (COVID-19). Moderate and severe COVID-19 patients with the acute respiratory syndrome were recruited at the Tongji Hospital, and USWD was administered for 10 minutes twice daily for 12 consecutive days along with standard medical treatment (USWD group, n = 25), versus standard medical treatment alone (control group, n = 25). The analyses indicated significantly reduced time to clinical recovery in patients in the USWD group than those in the control group. Moreover, seven-category ordinal and systemic inflammatory response syndrome scores were improved in the USWD group on day 28 than in the control group. Additionally, no treatment-associated adverse events or worsening of pulmonary fibrosis were observed in the USWD group. We believe that our study makes a significant contribution to the literature because this is the first randomized clinical trial investigating the efficacy of USWD treatment in COVID-19. Furthermore, USWD as an adjunctive therapy shortened the recovery course and improved the clinical status of patients with COVID-19 without significant adverse events, providing an opportunity to improve the condition of patients worldwide. Further, we believe that this paper will be of interest to the readership of your journal because it provides a new aspect for improving the clinical recovery and rehabilitation of patients with COVID-19, and thus, adheres to the Aims and Scope of the journal. Moreover, USWD group showed no change in the negative SARS-CoV-2 conversion rate, suggesting that the therapeutic effect of USWD is independent of the direct antiviral activity. Finally, the promising pilot-study findings, with no adverse events in the patients, warrant further multi-centre, large-cohort trials to confirm the efficacy of USWD in patients with COVID-19.
Data Availability
The trial data could be provided by a reasonable request to the corresponding authors (HC).
http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000029972
